1531. Early Real-World Experience of Long-Acting Cabotegravir (CAB) for HIV Pre-Exposure Prophylaxis (PrEP) in a Large Community-Based Clinic Network (CAN Community Health): Utilization and PrEP Persistence

BACKGROUND: Cabotegravir (CAB) is the first long-acting injectable form of HIV pre-exposure prophylaxis (PrEP) approved by the FDA on December 20, 2021. We assessed real-world utilization and adherence to Cabotegravir for PrEP in an outpatient community-based network in the United States (US). METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Altamirano, Jessica A, Shukla, Prerak, Barnett, Steven K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677704/
http://dx.doi.org/10.1093/ofid/ofad500.1366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677704/
http://dx.doi.org/10.1093/ofid/ofad500.1366

Ejemplares similares